+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Gynecological Cancer Drugs Market by Indication, Drug Class, Distribution Channel, End-users - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5887490
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Gynecological Cancer Drugs Market grew from USD 9.36 billion in 2023 to USD 10.35 billion in 2024. It is expected to continue growing at a CAGR of 11.95%, reaching USD 20.65 billion by 2030.

The scope of the gynecological cancer drugs market involves the research, development, and distribution of pharmaceuticals specifically targeting cancers that affect the female reproductive system, including ovarian, cervical, uterine, vaginal, and vulvar cancers. The necessity of these drugs is driven by the demand for effective treatment options to manage and potentially cure these types of cancers, which significantly impact women’s health globally. The application of gynecological cancer drugs lies in various treatment modalities like chemotherapy, immunotherapy, and targeted therapy, each aiming to improve patient outcomes with minimal side effects. End-users include hospitals, cancer treatment centers, and specialty clinics that provide oncology services.

Key growth factors influencing this market include increasing awareness and early diagnosis of gynecological cancers, advancements in medical technology, and ongoing clinical trials that contribute to innovative treatment options. Furthermore, government support and funding for cancer research are boosting the market potential. Potential opportunities are emerging in precision medicine and personalized treatment approaches, which can offer tailored therapies based on individual genetic profiles. Companies are recommended to invest in research and collaboration with academic institutions to spearhead drug discovery and development.

However, the market faces limitations such as high treatment costs, stringent regulatory requirements, and challenges in reaching underdeveloped regions where healthcare access is limited. Moreover, the side effects associated with existing treatments can affect patient adherence and outcomes.

Innovative research areas ripe for exploration include developing next-generation biologics, exploring combinatorial therapies, and utilizing artificial intelligence for drug discovery processes. The nature of this market is dynamic and competitive, with a strong emphasis on technological advancements and collaborative efforts to tackle unmet medical needs. Future growth will likely hinge on companies’ abilities to innovate continually, navigate regulatory landscapes effectively, and address patient-centric approaches to therapy. Businesses are advised to leverage data-driven insights and adopt flexible strategies to stay ahead in this evolving market landscape.

Understanding Market Dynamics in the Gynecological Cancer Drugs Market

The Gynecological Cancer Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of various gynecological cancers
    • Increasing aging female population and rising healthcare awareness
    • Government initiatives to develop both therapeutic and preventive drugs
  • Market Restraints
    • High cost and quality issues associated with formulation of gynecological cancer drugs
  • Market Opportunities
    • Development and introduction of novel ovarian cancer treatments
    • Increasing investments to modernized healthcare infrastructure and novel drugs
  • Market Challenges
    • Stringent regulatory frameworks associated with approval of drugs

Exploring Porter’s Five Forces for the Gynecological Cancer Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Gynecological Cancer Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Gynecological Cancer Drugs Market

External macro-environmental factors deeply influence the performance of the Gynecological Cancer Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Gynecological Cancer Drugs Market

The Gynecological Cancer Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Gynecological Cancer Drugs Market

The Gynecological Cancer Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Gynecological Cancer Drugs Market

The Gynecological Cancer Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gynecological Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc., Apotex Pharmaceutical Holdings Inc., AstraZeneca PLC, Bayer AG, Biocon Limited, Bristol-Myers Squibb Company, Clovis Oncology, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline PLC, ImmunoGen, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., TherapeuticsMD Inc., and VBL Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Gynecological Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Indication
    • Cervical Cancer
    • Chemotherapy
    • Ovarian & Fallopian Tube Cancer
    • Uterine Cancer
    • Vaginal Cancer
    • Vulvar Cancer
  • Drug Class
    • Alkylating Agent
    • Anthracyclines
    • Antitumor Antibiotic
    • Plant Alkaloid
  • Distribution Channel
    • E-commerce
    • Hospital Pharmacies
    • Retail Pharmacies
  • End-users
    • Clinics
    • Hospitals
    • Specialized Cancer Treatment Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of various gynecological cancers
5.1.1.2. Increasing aging female population and rising healthcare awareness
5.1.1.3. Government initiatives to develop both therapeutic and preventive drugs
5.1.2. Restraints
5.1.2.1. High cost and quality issues associated with formulation of gynecological cancer drugs
5.1.3. Opportunities
5.1.3.1. Development and introduction of novel ovarian cancer treatments
5.1.3.2. Increasing investments to modernized healthcare infrastructure and novel drugs
5.1.4. Challenges
5.1.4.1. Stringent regulatory frameworks associated with approval of drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Gynecological Cancer Drugs Market, by Indication
6.1. Introduction
6.2. Cervical Cancer
6.3. Chemotherapy
6.4. Ovarian & Fallopian Tube Cancer
6.5. Uterine Cancer
6.6. Vaginal Cancer
6.7. Vulvar Cancer
7. Gynecological Cancer Drugs Market, by Drug Class
7.1. Introduction
7.2. Alkylating Agent
7.3. Anthracyclines
7.4. Antitumor Antibiotic
7.5. Plant Alkaloid
8. Gynecological Cancer Drugs Market, by Distribution Channel
8.1. Introduction
8.2. E-commerce
8.3. Hospital Pharmacies
8.4. Retail Pharmacies
9. Gynecological Cancer Drugs Market, by End-users
9.1. Introduction
9.2. Clinics
9.3. Hospitals
9.4. Specialized Cancer Treatment Centers
10. Americas Gynecological Cancer Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Gynecological Cancer Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Gynecological Cancer Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. GYNECOLOGICAL CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. GYNECOLOGICAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. GYNECOLOGICAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GYNECOLOGICAL CANCER DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN & FALLOPIAN TUBE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VAGINAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLANT ALKALOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALIZED CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 40. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 44. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 62. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 66. INDIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. INDIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. INDIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. INDIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. INDONESIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. INDONESIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 74. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. MALAYSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. MALAYSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. PHILIPPINES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. PHILIPPINES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. SINGAPORE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. SINGAPORE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. TAIWAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. TAIWAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 98. THAILAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. THAILAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. THAILAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. THAILAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. VIETNAM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. VIETNAM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 111. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 115. EGYPT GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. EGYPT GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. EGYPT GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. EGYPT GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 119. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 123. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 127. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. ISRAEL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. ISRAEL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 135. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. NIGERIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. NIGERIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 147. NORWAY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. NORWAY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. NORWAY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. NORWAY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 151. POLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. POLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. POLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. POLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 155. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. SWITZERLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. SWITZERLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 183. TURKEY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. TURKEY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. TURKEY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. TURKEY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 195. GYNECOLOGICAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 196. GYNECOLOGICAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Gynecological Cancer Drugs Market, which are profiled in this report, include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apotex Pharmaceutical Holdings Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Clovis Oncology
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline PLC
  • ImmunoGen, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD Inc.
  • VBL Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information